ARTYX is a biopharmaceutical company that discovers and develops therapies for osteoarthritis, the most prevalent joint disease with unmet needs for disease-modifying pharmaceuticals and new, more effective and safe pain medications. ARTYX integrates advanced concepts in osteoarthritis pathogenesis, disease-specific target identification and clinical development strategies in product-focused programs. The lead product ART144 is in Phase II/III development. ART144 is is administered by injection into the joint and has proven to be safe and effective in two clinical studies. ART237, an intraarticular therapy for acute and chronic consequences of joint injury is in advanced stages of preclinical development. ARTYX is using proprietary delayed-release drug formulations for intraarticular injection
